Search - tctmd.com

Displaying 161 - 180 of 258

Sort: Relevancy | Date

Presentation TCT 2016

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Davide Capodanno

October 30, 2016

Presentation TCT 2016

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, C. Michael Gibson

October 30, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Rationale for and Design of ISCHEMIA: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Bernard J. Gersh

October 30, 2016

Presentation TCT 2016

Rationale for and Design of COMPLETE: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Anthony H. Gershlick

October 30, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

Todd Neale

October 29, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presenter: Nicole Ibrahim, Saibal Kar, Zoltan G. Turi

October 14, 2015

News Conference News TCT 2015

Trial Results Often Struggle to Keep Pace With Evolving Technology

Nicole Lou

October 13, 2015

News Conference News TCT 2015

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

October 13, 2015

News Conference News TCT 2015

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Todd Neale

October 13, 2015

News Conference News TCT 2015

Experts Say ‘Big Data’ Represents Future of Health Care Research

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Advertisement

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Rationale for and Design of ISCHEMIA: What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of COMPLETE: What I Expect the Findings to Be But What Wont Surprise Me!

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

My Takeaways From TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Trial Results Often Struggle to Keep Pace With Evolving Technology

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Experts Say ‘Big Data’ Represents Future of Health Care Research

Discussion Highlights Merits, Limitations of Small Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content